As AstraZeneca’s share price dips 4%, is it time for me to buy more?

Despite its 12-month increase, AstraZeneca’s share price appears very undervalued to me, and looks set to rise on strong growth to 2030.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Hand of person putting wood cube block with word VALUE on wooden table

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca’s (LSE: AZN) share price has dropped around 4% from its 26 June 12-month traded high of £127.04.

However, this still leaves it about 28% up from its 12-month low of 12 February.

As a shareholder who bought at much lower prices, is now a good time for me to buy more?

Should you invest £1,000 in Atlantic Lithium Limited right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Atlantic Lithium Limited made the list?

See the 6 stocks

How does it look technically?

AstraZeneca trades on the key price-to-earnings ratio (P/E) of stock valuation measurement at 38.8. This is still bottom of the list of its key international peers, which have an average P/E of 90.4.

This comprises Novo Nordisk at 45.2, AbbVie at 51.5, Eli Lilly at 127, and Merck at 138.1.

That said, its closest UK peer – GSK – has a P/E of 13.8, which according to my analysis is around 67% undervalued against its own peer group.

However, AstraZeneca is much bigger than GSK – ranked globally by market capitalisation respectively at number seven and number 18. 

Using the same discounted cash flow methodology as I did for GSK, AstraZeneca is 42% undervalued at its current £122.55.

Therefore, a fair value for the shares would be £211.29, although they may go lower or higher than that.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL23 Jul 201923 Jul 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

Growth projections

Back in 2014, AstraZeneca announced its target of increasing revenues to more $45bn+ by 2023 (from the then-$26.5bn). Didid it make it? Yes, revenues came in at $45.8bn.

In its recent 21 May ‘Ambition 2030 and Beyond’ presentation, it said it will deliver $80bn in revenues by 2030.  

It added that it is on track to deliver mid-30% core operating margin by 2026. After that, it will still target at least mid-30%, although it said this will be influenced by portfolio evolution.

Its Q1 2024 results released on 25 April showed revenue up 19% year on year to $12.679bn. That was driven by an 18% increase in product sales.

One risk to the firm’s projections is that a failure in any of its key drugs could be very costly. Also potentially very expensive would be any legal action arising from the ill effects of any of its medicines.

That said, consensus analysts’ expectations are that AstraZeneca’s earnings will grow 15.7% a year to end-2026. Earnings per share are anticipated to increase 16.5% a year to that point.

So will I buy?

As a long-term investor now rather than the trader I was when younger, I am in an investment for the duration, at least until I sell my remaining growth stocks and focus solely on high-dividend-paying ones.

That said, my average entry price for my AstraZeneca holding is a lot lower than the current price. To buy more at this level would dramatically increase the risk of any major adverse price moves on my profit.

Consequently, I am happy with my current position and will not buy more.

However, if I did not have this I would have no hesitation in starting a position at the current price. I think there is every chance that AstraZeneca will achieve its new growth targets, just as it did before.

And at roughly double the current revenues, these should drive the share price higher over time, in my view.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »